Hengrui Medicine: Subsidiary Receives Approval Notice for Clinical Trials of SHR-1316 Injection

Hengrui Pharmaceuticals announced that the company has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-1316 injection, and will soon start clinical trials. The drug is a humanized anti-PD-L1 monoclonal antibody subcutaneous formulation independently developed by the company, intended for first-line treatment of extensive-stage small cell lung cancer. As of now, the cumulative research and development investment in the related project is about 815 million yuan.